Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowFRA:3IP -0.60%76 Dividend Yield % is 0.00% as of Aug. 20, 2026. GuruFocus rates FRA:3IP with a GF Score™ of 76/100 and a GF Value™ of €33.34 (Fairly Valued). The stock has 4 warning signs investors should review. Among 507 Drug Manufacturers companies, Harrow ranks worse than 197238.46% on this metric.
As of today (2026-08-20), the Trailing Annual Dividend Yield of Harrow is 0.00%.
The historical rank and industry rank for Harrow's Dividend Yield % or its related term are showing as below:
FRA:3IP's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.97 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Harrow's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3IP vs XERS, PRGO, PAHC: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Harrow's Dividend Yield % falls into.
Harrow (FRA:3IP) has a Dividend Yield % of 0.00% as of Aug. 20, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Harrow and its competitors. According to the industry distribution chart, Harrow ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Harrow's Dividend Yield % too high?
Harrow's current Dividend Yield % is 0.00%. Based on the distribution chart, Harrow ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Harrow has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's Dividend Yield % compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #999999 out of 507 companies for Dividend Yield %. This places Harrow in the lower half of its industry. The industry median Dividend Yield % is 1.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.97, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Harrow and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (FRA:3IP) is currently considered Fairly Valued. The stock's GF Value™ is €33.34, compared to a current price of €33.00 — trading 1% below its estimated fair value. The current Dividend Yield % is 0.00%. Harrow's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Harrow (FRA:3IP), the current Dividend Yield % is 0.00% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (FRA:3IP) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of €33.00 is trading 1% below its estimated GF Value™ of €33.34.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for FRA:3IP:
Dividend Yield %: 0.00%
GF Value™: €33.34 vs. price of €33.00 (1% below fair value)
No single metric tells the full story. See the FRA:3IP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
76GF Score
Get the complete analysis for FRA:3IP
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3IP has been successfully added to your 
